

1 HAGENS BERMAN SOBOL SHAPIRO LLP  
Shana E. Scarlett (SBN 217895)  
2 715 Hearst Avenue  
Berkeley, California 94710  
3 Telephone: (510) 725-3000  
Facsimile: (510) 725-3001  
4 shanas@hbsslaw.com

5 Steve W. Berman (*Pro Hac Vice* pending)  
HAGENS BERMAN SOBOL SHAPIRO LLP  
6 1918 Eighth Avenue, Suite 3300  
Seattle, WA 98101  
7 Telephone: (206) 623-7292  
Facsimile: (206) 623-0594  
8 steve@hbsslaw.com

9 HAGENS BERMAN SOBOL SHAPIRO LLP  
Robert B. Carey (*Pro Hac Vice* pending)  
10 11 West Jefferson, Suite 1000  
Phoenix, Arizona 85003  
11 Telephone: (602) 840-5900  
Facsimile: (602) 840-3012  
12 rob@hbsslaw.com

13 Attorneys for Plaintiff

14 (Additional Counsel on signature page)

15 UNITED STATES DISTRICT COURT

16 NORTHERN DISTRICT OF CALIFORNIA

17 CASEY JONES, individually and on behalf of  
all others similarly situated,

18 Plaintiff,

19 v.

20 THERANOS, INC., a California Corporation,

21 Defendant.  
22

No. 3:16-cv-02835

CLASS ACTION COMPLAINT

**DEMAND FOR JURY TRIAL**

TABLE OF CONTENTS

Page

I. INTRODUCTION ..... 1

II. PARTIES ..... 1

III. JURISDICTION AND VENUE..... 2

IV. BACKGROUND..... 2

V. FACTUAL ALLEGATIONS CONCERNING PLAINTIFF..... 20

VI. CLASS ALLEGATIONS ..... 22

VII. CAUSES OF ACTION..... 24

FIRST CAUSE OF ACTION (BREACH OF CONTRACT) ..... 24

SECOND CAUSE OF ACTION (ARIZONA CONSUMER FRAUD) (ARIZONA  
SUBCLASS ONLY) ..... 25

THIRD CAUSE OF ACTION (VIOLATION OF THE UNFAIR COMPETITION ACT,  
CALIFORNIA BUSINESS & PROFESSIONS CODE § 17200, *ET SEQ.*) ..... 26

FOURTH CAUSE OF ACTION (CONSUMER LEGAL REMEDIES ACT.)  
(CAL. CIV. CODE § 1750, *ET SEQ.*)..... 28

FIFTH CAUSE OF ACTION (VIOLATION OF THE UNFAIR COMPETITION ACT,  
CALIFORNIA BUSINESS & PROFESSIONS CODE § 17500, *ET SEQ.*) ..... 29

SIXTH CAUSE OF ACTION (UNJUST ENRICHMENT)..... 31

REQUEST FOR RELIEF..... 32

DEMAND FOR JURY TRIAL ..... 32

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**I. INTRODUCTION**

1  
2 1. Used for diagnostics and prevention, accurate, reliable, timely blood tests are a critical  
3 component of a patient’s healthcare. Inaccurate tests cause emotional distress, lead to unnecessary  
4 and improper medical care, and endanger patients’ health and lives.

5 2. To avoid these problems, lab operators must follow established policies and  
6 procedures, provide accurate information about the test—so patients’ decisions are grounded in  
7 fact —and ensure that test results are not needlessly inaccurate.

8 3. Founded in 2003 by Elizabeth Holmes, Theranos, Inc. claims to be a “consumer  
9 health technology company,” one that entered the laboratory testing market and focused on blood-  
10 based tests.

11 4. According to its website, its “mission is to make actionable health information  
12 accessible to people at the time it matters, enabling early detection and prevention of disease, and  
13 empowering people with information to live the lives they want to live.”

14 5. As revealed in this Complaint, Theranos was focused more on press and market value  
15 than the health of its customers, and it achieved the opposite of its mission: it obfuscated its actions  
16 and tests to where no reasonable consumer can rely on the results provided or make health care  
17 decisions based on them.

18 6. Plaintiff sues to address these massive failures on issues relating to customer health,  
19 including Theranos using substandard laboratory policies and procedures, failing to honor the  
20 promises it made about testing accuracy and quality, concealing and obscuring the truth about the  
21 invasiveness of the tests, providing inaccurate test results to patients and not correcting those results  
22 when possible after a reasonable person would understand the results were or could be erroneous,  
23 and misrepresenting the technological advances that Theranos allegedly developed.

**II. PARTIES**

24  
25 7. Defendant Theranos is a California corporation with its principal place of business at  
26 1701 Page Mill Road Palo Alto, California 94304.

27 8. Theranos operates blood testing labs in California and Arizona.

28 9. Plaintiff Casey Jones is a resident of Maricopa County, Arizona.

**III. JURISDICTION AND VENUE**

10. This Court has original jurisdiction over this action under 28 U.S.C. § 1332(a) and (d). In the aggregate, Plaintiff’s claims and the claims of other Class members exceed \$5,000,000, exclusive of interest and costs, and numerous Class members are citizens of different states than Defendant Theranos.

11. This Court has personal jurisdiction over Plaintiff because Plaintiff submits to the Court’s jurisdiction. This Court has personal jurisdiction over Defendant because Defendant is headquartered in the District and conducts substantial business in the District. Many of the actions establishing the Complaint took place in the District, to include upon information and belief the creation and final approval of the allegedly false marketing materials.

12. Venue is proper in this District under 28 U.S.C. § 1391 because Defendant, as a corporation, is “deemed to reside in any judicial district in which they are subject to personal jurisdiction,” and because many decisions behind the scheme to mislead consumers regarding the accuracy, reliability, and operation of the Theranos blood tests were made in this District.

13. Because Theranos resides in the District, transacted business within the District, and a substantial part of the events establishing the claims arose in this District, venue is proper.

**IV. BACKGROUND**

14. For its first retail endeavor, Theranos joined with Walgreens to bring its self-proclaimed “revolutionary” blood tests directly to the public, hoping to eventually provide its services nationwide.

15. Theranos went live with its Walgreens venture in September 2013, and eventually opened 56 “Theranos Wellness Centers” in Arizona and California.

16. The Theranos Wellness Centers are physically located in Walgreens, and staffed by Theranos employees.

17. Theranos also opened two non-Walgreens based Theranos Wellness Centers, one at the downtown Phoenix campus of Arizona State University and the other at the Generations Medical Center in Tempe, Arizona.

1 18. In addition to providing space for the Theranos Wellness Centers, Walgreens helped  
2 fund Theranos with a \$50 million financing arrangement and assisted Theranos in scheduling and  
3 collecting payments from consumers.

4 19. At the Wellness Centers, Theranos offered a comprehensive slate of some 200 lab  
5 tests.

6 **theranos**

7 **the blood tests that need just a**  
8 **tiny sample.**

9 **Walgreens partners with Theranos to provide**  
10 **lab services**

11 Theranos is working to shape the future of lab  
12 testing. Now, for the first time, their high-  
13 complexity CLIA-certified laboratory can perform  
14 your tests quickly and accurately using tiny  
15 samples.<sup>1</sup>

16 [Learn more at Theranos.com](#)

17 [Para información en español haga clic aquí](#)



18 20. The key feature Theranos used to market its tests and differentiate itself was that it  
19 brought a new technology and approach to the staid, established blood test industry. Its tagline: “one  
20 tiny drop changes everything.” This theme was prominent in its advertisements: Theranos boasted it  
21 could analyze samples as small as 1/1,000 the size of the typical blood draw and perform tests on any  
22 sample type, including blood, urine, and other samples. “It’s fast, easy, and the highest level of  
23 quality,” Theranos informed prospective customers. Theranos stressed it used smaller samples and  
24 less invasive techniques, pushing this difference in advertisements and on company web pages:


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**goodbye, big bad needle.**

Instead of a huge needle, Theranos-trained technicians can use a tiny finger stick<sup>2</sup> or collect a micro-sample from a venous draw.<sup>2</sup> It's practically painless and a lot less scary. Now the entire lab testing process is comfortable, accommodating, and less intimidating—for people big and small.




Smaller sample. Massive impact.



Oncology

Smaller samples are better for cancer patients. Making it easier for them to get tested when needed.



Pediatrics

Smaller samples are better for children. Minimizing the fear and pain associated with traditional labs.




Geriatrics

Smaller samples are better for older patients. Who can have difficulty with collapsed veins.

21. It also advertised its venous blood draws used smaller needles and smaller tubes.

22. Despite using tests requiring only a little blood, Theranos promised consumers it could still deliver the best in accuracy and quality.



1 23. It announced that it would “realize our mission only when our tests are performed to  
2 the highest standards of quality.

3 24. It endorsed that getting accurate results in a timely manner is essential, declaring  
4 “what you decide about your health should be informed and timely enough to protect or improve it.



**fast results. fast answers.**

Theranos performs their test analyses fast, so they can return results to your clinician<sup>3</sup> faster than ever before.<sup>3</sup> That means a more timely diagnosis to support better, more informed treatment.

10  
11 25. Theranos summed up its approach this way, “Our technology and our process are all  
12 configured to put you and your preventive outcomes first.”

13 26. Theranos claimed vigilance in providing the highest quality tests. “We continuously  
14 conduct proficiency testing and participate in multiple proficiency testing programs,” and all of our  
15 “tests are developed and validated under and to the CLSI, FDA, Centers for Disease Control and  
16 World Health Organization guidelines,” touting that it had “processed hundreds of thousands of tests  
17 in validating our work for 10 of the 15 largest pharmaceutical companies.”

18 27. It claimed to have performed “more than six million tests in the nearly two years since  
19 we began serving individuals and physicians through our clinical labs,” and worked with over 9,000  
20 physicians.

21 28. Theranos claimed it was leading the industry in transparency.

22 Theranos is the first lab to commit to voluntarily submitting its  
23 laboratory developed tests to the FDA. We are working to build a  
24 model for the transition to the FDA framework. We are doing this even  
25 though we don’t need to – opening up to regulators like no lab before.

26 29. Theranos also claims to be leading the lab industry in transparency by publishing  
27 Proficiency Testing performance statistics.

28 30. It boasted its consumer experience was all-around better. “Our tests use less blood to  
make the testing experience as wonderful as possible for everyone.”

1           31.     “Theranos’ revolutionary lab services make tests more efficient, convenient, and  
2 affordable than ever before.”

3           32.     To help sell its products, Theranos preached that patients should have and deserved  
4 timely, accurate information, so they could “engage with their own health and begin working with  
5 their doctors preventatively.”

6           33.     To help further its bottom line, Theranos pushed to change Arizona law, and  
7 succeeded. Arizona became the first state to allow consumers to purchase a blood test without a  
8 provider’s order and to “expressly recognize[] individual’s [sic] rights to their own health  
9 information.”

10          34.     To accomplish this, Theranos worked closely with leaders in Arizona. Its assistance  
11 came from the top: Arizona Governor Doug Ducey wholeheartedly adopted Theranos’ claims and  
12 pressed to change the law for Theranos to do business.

13          35.     Theranos’ lobbying resulted in Ducey having a favorable impression: “My  
14 administration is focused on making Arizona the easiest and most attractive place in the nation for  
15 21st-century companies like Theranos to operate and grow. By reducing burdensome regulations and  
16 red tape, this law not only shows innovative companies we’re open and ready for business, it also  
17 gives Arizonans access to more efficient, cost-effective services while promoting preventive health  
18 care and price transparency. That’s good for business, good for patients and providers, and good for  
19 taxpayers – an all-around win for Arizona.”

20          36.     Later, Elizabeth Holmes in a letter to the editor of the Arizona Republic on  
21 December 1, 2015, reiterated Theranos’ commitment to the highest standards for testing and quality:  
22 “Theranos fought for direct access in Arizona to bring high-quality ... lab testing to everyone. We  
23 have fought—and always will fight—for the highest quality standards for Arizonans....”

24          37.     In lobbying to change the law, Theranos disseminated claims of astonishing  
25 advancements in the lab testing industry.

26          38.     “We can perform hundreds of tests, from standard to sophisticated, from a pinprick  
27 and tiny sample of blood, and we have performed more than 70 tests from a single tiny sample,” said  
28 a Theranos representative.



1           39. According to Holmes, the claim went even further—Theranos’ new technology  
2 applied across the board: “Every test that we offer in our lab can be run on our proprietary devices.”  
3 Espousing this claim—that the Edison machines can run all tests Theranos submitted to the FDA—  
4 on a nationally syndicated financial TV program helped bolster Theranos’ prospects and reputation  
5 with many stakeholders.

6           40. At some point, money came easy to Theranos as its reputation grew. According to  
7 CrunchBase, Theranos raised:

8  
9 **Funding Rounds (8) - \$686.3M**

UPDATE

Date	Amount / Round	Valuation	Lead Investor	Investors
Mar, 2015	\$348.5M / Private Equity	—	—	0
Feb, 2014	\$198.9M / Private Equity	—	—	0
Sep, 2013	\$50M / Undisclosed	—	Walgreens	1
Jul, 2010	\$45M / Venture	—	—	0
Nov, 2006	\$28.5M / Series C	—	—	4
Feb, 2006	\$9.1M / Series B	—	—	1
Feb, 2005	\$5.8M / Series A	—	—	0
Jun, 2004	\$500k / Seed	—	Draper Fisher Jurvetson (DFJ)	1

10  
11  
12  
13  
14  
15  
16  
17           41. Theranos adeptly spun its storyline about its successes and “revolutionary” testing. It  
18 pushed and embraced positive, glowing reports of the company’s “transformative” nature and  
19 industry-changing technologies. These efforts spanned the media spectrum—old and new, big and  
20 small—including The Wall Street Journal, Business Insider, San Francisco Business Times, Fortune,  
21 Forbes, Medscape, and Silicon Valley Business Journal. The reports adopt Theranos’ assessment that  
22 its work is novel and the coming of a “golden idea”:

- 23           • “Theranos: The Biggest Biotech You’ve Never Heard of.”
- 24           • San Francisco Business Times, August 30, 2013.
- 25           • “Elizabeth Holmes: The Breakthrough of Instant Diagnosis.”
- 26           • Wall Street Journal, September 8, 2013.
- 27           • “Creative disruption? She’s 29 and Set to Reboot Lab Medicine.”
- 28           • MedPageToday, November 18, 2013.

- 1 • “This CEO is Out for Blood.”
- 2 • Fortune, June 12, 2014.
- 3 • “Bloody Amazing.”
- 4 • Forbes, 7/2 and 7/21, 2014.
- 5 • “Meet Elizabeth Holmes, Silicon Valley’s Latest Phenomenon.”
- 6 • San Jose Mercury News, July 15, 2014.
- 7 • “This Woman’s Revolutionary Idea Made Her A Billionaire—And Could
- 8 Change Medicine.”
- 9 • Business Insider, September 29, 2014.
- 10 • “She’s America’s Youngest Female Billionaire - And a Dropout.”
- 11 • CNN/Money, October 16, 2014.
- 12 • “Here’s How the World’s Youngest Self-Made Female Billionaire Shows
- 13 People She’s In Charge.”
- 14 • Business Insider, December 8, 2014.
- 15 • “Top 10 Most Innovative Companies in Health Care, 2015: #7, Theranos.”
- 16 • Fast Company, February 2015.
- 17 • “Theranos CEO: Avoid Backup Plans.”
- 18 • INC., Stanford Business School, February 10, 2015.
- 19 • “Elizabeth Holmes: 2015 Horatio Alger Award Winner.”
- 20 • Horatio Alger Association, March 9, 2015.
- 21 • “Theranos One Step Closer to Consumerizing Health.”
- 22 • Decibio, April 8, 2015.
- 23 • “Elizabeth Holmes.” 100 Most Influential People edition.
- 24 • TIME, April 16, 2015.
- 25 • “World’s Youngest Billionaire - Another Steve Jobs?”
- 26 • CNBC, April 27, 2015.
- 27 • “Airbnb Chesky, Theranos Holmes among presidential entrepreneurs.”
- 28 • USAToday, May 11, 2015.
- “Personalized Technology Will Upend the Doctor-Patient Relationship”

- 1 • Harvard Business Review, June 19, 2015.
- 2 • “Disruptive Diagnostics Firm Theranos Gets Boost from FDA.”
- 3 • Fortune, July 2, 2015.
- 4 • “Theranos’ Holmes Marks 50th Anniversary of Medicare and Medicaid with  
5 Vision for Next 50 Years.”
- 6 • Business Wire, July 30, 2015.
- 7 • “Elizabeth Holmes on Using Business to Change the World.”
- 8 • Forbes, October 5, 2015.
- 9 • “How Theranos is Disrupting the Health Care Industry.”
- 10 • Bloomberg, October 6, 2015.
- 11 • “Theranos Founder Elizabeth Holmes to Deliver Keynote Address at 2015  
12 Medical Innovation Summit.”
- 13 • Crain’s Cleveland Business, October 7, 2015.
- 14 • “Theranos’ Elizabeth Holmes Call on Women to Help Each Other.”
- 15 • Fortune, October 12, 2015.
- 16 • “CME Group Announces Elizabeth Holmes as the 2015 Melamed-Arditti  
17 Innovation Award Recipient.”
- 18 • MarketWatch, October 12, 2015.

18 42. The result of Theranos’ promotional efforts: a market value over \$9 billion by 2014  
19 and a CEO widely acclaimed as one of the most successful entrepreneurs in the world—and one of  
20 the youngest billionaires ever.

21 43. Theranos purposely ginned up excitement and funding, pushed it was disrupting an  
22 antiquated, stodgy industry, and shrouded its product in secrecy. Theranos, however, didn’t keep its  
23 promises that its services allow consumers to proactively engage in their own healthcare decisions  
24 using accurate, timely information provided by Theranos. As one health reporter said, “New  
25 innovations can’t simply surf on excitement when people’s lives are at stake.”

26 44. Theranos also advertised its tests on Walgreen’s website promising a test that would  
27 support “better, more informed treatment”:  
28



- the lab test,  
reinvented.

At Theranos, we're working to bring about a day when lab testing is accessible and affordable for everyone. So people can engage with their health and their physicians like never before, and no one has to say goodbye too soon.

[Learn more at theranos.com >](#)

- Visiting or living in Arizona?

[Learn more about Direct Access testing at Theranos Wellness Centers >](#)

- **Theranos is easy to find.**

You can find Theranos Wellness Center™ locations inside select Walgreens in the greater Phoenix, AZ area. With extended hours, including nights and weekends it's easy to fit your tests into your busy schedule.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28


**Comprehensive  
Metabolic Panel (CMP)**

**\$7.27**

Other Labs:  
\$27 - \$29

To evaluate organ function and check for conditions such as diabetes, liver disease, and kidney disease

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28




To evaluate  
thyroid function

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28



To screen for and diagnose sexually transmitted infections



16 To help evaluate  
17 insulin production

- 18 • Fast results. Fast answers.

19  
20 At Theranos, we've dramatically reduced the time it takes to analyze samples. So you and  
21 your physician get your results faster than ever before.<sup>1</sup> Which means a more timely  
22 diagnosis to support better, more informed treatment. So you can engage with your  
23 physician, and your health, like never before.<sup>1</sup>

24 45. Behind the claims of revolution and disruption, there were unfounded, false,  
25 deceptive, and misleading claims of superiority over existing systems and practices.

26 46. First, Theranos' labs were negligently maintained and operated and it did not follow  
27 proper procedures and policies.

28 47. On March 18, 2016, Centers for Medicare & Medicaid Services wrote Theranos to  
notify it of proposed sanctions against Theranos' Clinical Laboratory Improvement Amendments of



1 1988 (CLIA) certificate. CLIA is a federal regulatory standards program whose goal is to ensure  
2 accuracy, reliability and timeliness of test results, regardless of where the test was performed, for all  
3 clinical laboratory tests on humans.

4 48. CMOS conducted a CLIA recertification and complaint survey at Theranos’  
5 laboratory, completing its onsite portion on November 20, 2015 and concluding the survey on  
6 December 23, 2015.

7 49. Based on this survey, Theranos was out of compliance with five CLIA Condition-  
8 level requirements, including (a) D5024: 42 C.F.R. § 493.1215; (b) D5400: 42 C.F.R. § 493.1250;  
9 (c) D6076: 42 C.F.R. § 493.1441; (d) D6108: 42 C.F.R. § 493.1447; and (e) D6168: 42 C.F.R.  
10 § 493.1487.

11 50. In a January 25, 2016, letter, CMS outlined these deficiencies and notified Theranos  
12 of the seriousness of the deficiencies under 42 C.F.R. § 493.1215, which resulted in a finding of  
13 immediate jeopardy to patient safety and health, and demanded immediate action to remove the  
14 jeopardy and come into compliance.

15 51. Theranos, after requesting an extension, responded on February 12, 2016.

16 52. After reviewing Theranos’ response, CMS concluded that Theranos’ response did not  
17 “constitute a credible allegation of compliance and acceptable evidence of correction for the  
18 deficiencies cited during the CLIA recertification and complaint survey completed on December 23,  
19 2015, and does not demonstrate that the laboratory has come into Condition-level compliance and  
20 abated immediate jeopardy.”

21 53. A credible allegation of compliance is a statement or document that is (1) made by a  
22 representative of a laboratory with a history of having maintained a commitment to compliance and  
23 taking corrective action when required; (2) realistic in terms of the possibility of corrective action  
24 being accomplished between the survey and the date of the allegation; and (3) indicates resolution of  
25 the problem.

26 54. The report found that Theranos’ blood tests often failed to meet the lab’s own  
27 standards, and that Theranos employed unqualified staff to review patient test results.

1           55.     According to the Wall Street Journal, which viewed an unredacted report, 13 tests  
2 conducted on Theranos' inventions performed poorly. Examples include (1) 29 percent of the quality  
3 control checks performed on the company's inventions in October 2014 fell outside the normal  
4 range; (2) a hormone test run on Theranos' proprietary machines failed 87 percent of quality control  
5 checks; and (3) a test used to detect prostate cancer failed quality control verifications 22 percent of  
6 the time between April and May 2015.

7           56.     Second, Theranos pushed its revolutionary, fast, minimally invasive techniques on  
8 cutting edge technology, yet that is not what consumers received when they went to the Walgreens  
9 stores.

10          57.     Theranos' new technology did not extend to its entire product line and, even where it  
11 did, it was not always used.

12          58.     Theranos told regulators it used the Edison, its proprietary device, for 12 types of tests  
13 out of over 200 types offered to consumers and stopped using the devices altogether in late June  
14 2015.

15          59.     Consumers arrived expecting to have minimal blood drawn and small needles or  
16 finger pricks, but they got conventional venous blood draws.

17          60.     Likewise, the tests were often then run on standard testing equipment (operated  
18 incorrectly or with inadequate training), not the novel technology touted in the promotional efforts or  
19 marketing material.

20          61.     Even when the technology existed, it wasn't used. Theranos consequently halted its  
21 finger-stick draws, collected in a small tube called a nanotainer, after the FDA declared the container  
22 was a medical device that should be regulated. Theranos ceased using its proprietary technology,  
23 nicknamed Edison, in June 2015.

24          62.     Theranos' Arizona lab handled the vast majority of blood samples collected at  
25 Arizona-based Walgreens locations and at Arizona State University's clinic and the Generations  
26 Medical Center.

1           63.     The June 2015 decision to cease using Edison did not affect the company’s Arizona  
2 lab because it exclusively used traditional FDA-approved blood analyzers and instruments made by  
3 companies such as Siemens and Olympus.

4           64.     Arizona patients could have blood drawn through capillary draw or venous draw, and  
5 the samples would be sent to the applicable lab by Theranos. But Theranos did not inform consumers  
6 it had new technology only for twelve of the 200 tests and that conventional equipment would be  
7 used for many tests. Nor did Theranos advise that the blood draw might not be the minimally  
8 invasive draw, a fact consumers learned only during the blood draw.

9           65.     Third, contrary to its mission statement, Theranos did not strive to provide accurate  
10 information to its consumers so they could make an informed choice.

11           66.     Its path to success was far from open and public. Despite its claims of transparency,  
12 Theranos kept information about its technology and blood tests secret.

13           67.     Holmes most descriptive statements, was that Theranos uses “the same fundamental  
14 chemical methods” as existing labs do, and its advances relate to “optimizing the chemistry” and  
15 “leveraging software” to permit those conventional methods to work with tiny sample volumes.

16           68.     Nor has Theranos engaged the scientific community. Theranos, to this day, has not  
17 published on its work in peer-reviewed biomedical literature. Reportedly, by January 5, 2015, a  
18 search for Theranos in PubMed returned only two unrelated articles co-authored by Theranos  
19 employees, neither of which offered insights about the company.

20           69.     Holmes has said the company has proof its tests are as accurate as traditional ones, but  
21 has provided no support for the statement.

22           70.     To allay criticism of Theranos’ tests, its spokesperson promised that Theranos  
23 planned to publish data “in the near future. Stay tuned!” Despite its promise, no data have been  
24 forthcoming on this topic.

25           71.     Theranos did not even disclose its methodologies to its medical services partners. As  
26 part of a “long-term strategic alliance” to use Theranos’ technology, the Cleveland Clinic and  
27 Theranos agreed to a joint study that would compare the effectiveness of Theranos’ approach to  
28 traditional approaches. In January, three Cleveland Clinic scientists visited Theranos’ headquarters,

1 where they were shown the company's Edison devices but Theranos did not show the scientists how  
2 the devices worked or provide written materials on how exactly the machines operated.

3 72. Because details of the Theranos technology have not been disclosed, peers cannot  
4 evaluate or comment on its claims. As a leading physician has noted, "The quality of the results are  
5 [sic] not known since the Theranos system has not been independently evaluated, nor do any  
6 published results exist to compare with conventional technologies. New diagnostic tests must be  
7 evaluated for their accuracy, precision, specificity and long-term robustness. Trueness and precision  
8 (accuracy) must be maintained over months or years, and monitored by external quality assurance  
9 programs, so that patient's data can be directly compared over long periods of time. Without  
10 independent validation, Theranos technology's quality and robustness will remain in question."

11 73. Without such review and assessment, patients receive the opposite of what was  
12 promised. They must manage their health based on assumptions and promises, not timely, accurate  
13 information.

14 74. Fourth, Theranos' promises of the highest levels of accuracy and quality are  
15 unfounded, false and misleading.

16 75. A study showed that Theranos' results are not as accurate as the two dominant players  
17 in the industry. In March 2016, Theranos' results were compared to those from LabCorp and Quest  
18 Diagnostics in a study funded by Icahn Institute for Genomics and Multiscale Biology and the Harris  
19 Center for Precision Wellness at the Icahn School of Medicine at Mount Sinai.

20 76. The percentages for measurements outside their normal range were 8.3%, 7.5%, and  
21 12.2% for LabCorp, Quest, and Theranos, respectively. Although LabCorp and Quest showed no  
22 significant difference in the rates of their tests outside the reference range, the odds ratio that  
23 Theranos reported a measurement outside its normal range compared with the other services was 1.6.

24 77. This increase in abnormal test results can have negative consequences for medicine—  
25 usually extra testing, additional patient visits to clinics or hospitals, and added doctor services, all of  
26 which result in additional costs and burdens to patients or to the healthcare system and are potentially  
27 harmful where the abnormal tests were misdiagnoses (*i.e.*, false positives).

1           78.     Nor did Theranos' labs meet state and federal standards—all of which are designed to  
2 protect patients.

3           79.     Arizona inspectors claimed that Theranos could not provide back-up data showing  
4 that it had fully validated three lab instruments used to analyze test samples despite federal  
5 regulations requiring labs to furnish such data.

6           80.     Theranos also failed to meet proficiency testing and lab-instrument validation  
7 requirements, which are key to ensuring patients and doctors get accurate results.

8           81.     During a separate inspection, the Federal Drug Administration issued 14  
9 “observations” after a review of Theranos' testing facilities in California from Aug. 25 through  
10 Sept. 16. Most findings addressed problems with quality-control issues, but notably the FDA  
11 determined Theranos' nanotainer was an unapproved medical device.

12           82.     Fifth, consumers are not getting what they paid for when they receive blood tests from  
13 Theranos.

14           83.     In May 2016, Theranos voided two years of test results—comprising tens of  
15 thousands of tests—from 2014 and 2015, and corrected some results and did not revise others,  
16 leaving the void results as the only result the consumer received.

17           84.     These tests were conducted on both Edison equipment and conventional tests, and at  
18 multiple labs.

19           85.     It was reported that the Arizona lab performed the blood-coagulation tests with a  
20 traditional machine from Siemens AG programmed to the wrong settings by Theranos, and failed  
21 several tests to gauge the purity of the water it used in its Siemens machines, which could affect the  
22 accuracy of some blood tests run on the devices.

23           86.     Brooke Buchanan, a Theranos spokeswoman, confirmed that Theranos “made  
24 mistakes in the past in the Newark” lab, which housed the Edison.

25           87.     Based on reports, both Theranos laboratories have been identified as operationally  
26 deficient in material ways.

27           88.     Theranos' cure for deficient results was to re-run tests using conventional means with  
28 either the residual blood from the minimal draw or with blood already tested (presumably an amount

1 that wouldn't work with traditional machines, since Theranos' approach was the "first time" testing  
2 was accomplished using small amounts of blood), calling into question the reliability of any re-  
3 testing program.

4 89. Theranos has also misrepresented the import of the timeliness of its results.

5 90. Theranos claims the usual delay of testing in centralized laboratories is approximately  
6 three days and that they will generate and deliver their data much faster (*e.g.*, within four hours).

7 91. But according to a leading practitioner, the three-day delay claim is not accurate. The  
8 bulk of laboratory testing in centralized laboratories is completed within an hour or two (calculated  
9 from time of sample collection to time of results posting for physician review). For these tests, the  
10 claim that Theranos gets results faster is false. While there may be some tests that takes days, not  
11 hours, those are typically situations where time is not critical for adjusting patient care and faster  
12 analysis will not assist patient management or outcomes.

13 **V. FACTUAL ALLEGATIONS CONCERNING PLAINTIFF**

14 92. On September 2, 2015, Casey Jones visited a Theranos Wellness Center at the  
15 Walgreen's located at 3960 E Chandler Blvd, Phoenix, AZ 85048, on orders from his physician,  
16 Dr. Matthew Anastasi, to obtain a blood panel as part of a routine annual physical.

17 93. One reason Mr. Jones considered having the blood tests performed at the Theranos  
18 Wellness Center was that he and his wife were trying to get pregnant at the time and the store had  
19 several advertisements regarding the ability to order additional labs by simply checking extra boxes  
20 on the requisition form.

21 94. One additional, voluntary test was titled "reproductive health." Because Mr. Jones and  
22 his wife were concerned with his reproductive health, Mr. Jones had the reproductive health test  
23 performed at the Theranos Wellness Center.

24 95. When Mr. Jones' doctor provided him with the lab order, he explained he could go to  
25 any lab he desired and provided him with maps to LabCorp and Theranos.

26 96. Dr. Anastasi spoke highly of Theranos as a new technology that is minimally  
27 invasive, requiring only a small "prick" of blood to perform the panel of tests. He also noted they are  
28 conveniently located in Walgreen's stores and are open for walk-in appointments.

1           97.     Besides the information he received from his doctor, Mr. Jones learned about  
2 Theranos from the heavy media coverage and business press about their founder and CEO and the  
3 self-proclaimed remarkable changes they were making to the industry.

4           98.     An additional benefit in choosing Theranos was the option to have results delivered  
5 immediately upon the completion of the tests via an Android app. Mr. Jones downloaded the app and  
6 received his lab results electronically.

7           99.     Based the ease of draw, convenience, implied accuracy and credibility of Theranos'  
8 new technology, and ability to obtain additional tests, Mr. Jones chose the option of having his tests  
9 performed at the Theranos Wellness Center.

10          100.    Convenience was important to Mr. Jones because the lab was in his neighborhood and  
11 he was about to leave town for a trip.

12          101.    Because some tests were ordered by his physician and others by Mr. Jones, the  
13 physician ordered tests were billed to his insurance and the tests ordered by Mr. Jones were paid by  
14 him personally that day.

15          102.    Mr. Jones paid \$77.70 for the tests he personally opted to have performed by  
16 Theranos.

17          103.    Theranos conducted approximately 69 tests: six tests were performed at the Theranos  
18 lab at 7373 Gateway Boulevard, Newark California, 94560 and approximately 63 tests were  
19 performed at the Theranos lab at 1365 N. Scottsdale Rd., Scottsdale Arizona 85257.

20          104.    Upon arriving at Walgreens, Mr. Jones' experience differed greatly from what was  
21 promoted. He had several large vials of blood drawn—upon information and belief the same as what  
22 he would have had drawn at any other lab. There was no disclaimer made to Mr. Jones about this  
23 apparent change in the blood draw procedure.

24          105.    The final report from Theranos, dated September 4, 2015.

25          106.    Shortly after the blood draw, Mr. Jones read that Theranos (a) has a technology that  
26 does not work and (b) has serious quality control problems in their labs.

27          107.    Because of the reported issues with Theranos, Mr. Jones has serious concerns about  
28 the lab results he received, including concerns regarding the reliability and accuracy of the tests.

**VI. CLASS ALLEGATIONS**

108. Under Rule 23 of the Federal Rules of Civil Procedure, Plaintiff seeks certification of the following class:

109. All consumers who purchased a Theranos blood test in California or Arizona.

110. Plaintiff also seeks certification of the following subclass.

111. Arizona Subclass: All consumers who purchased a Theranos blood test in Arizona.

112. Excluded from the Classes are Defendant; the officers, directors or employees of Defendant; any entity in which Defendant has a controlling interest; and any affiliate, legal representative, heir or assign of Defendant. Also, excluded from the Class are any federal, state or local governmental entities, any judicial officer presiding over this action and the members of his/her immediate family and judicial staff, and any juror assigned to this action.

113. Plaintiff does not know the exact number of Class members. But Theranos claims to have conducted millions of tests, meaning there are at least tens of thousands of Class members such that joinder of all Class members is impracticable.

114. The Class is easily determined by objective criteria using Defendant's own records, which by law must exist. Theranos knows where each test was performed, by whom, for whom, and when.

115. There are questions of law and fact common to the Class. Defendant's illegal business practices and unlawful omissions similarly impact Class members, all of whom purchased a Theranos blood test.

116. Plaintiff asserts claims that are typical of the Class. Plaintiff and all Class members have been subjected to the same wrongful conduct because they all purchased a Theranos blood test marketed and sold by Theranos using the same marketing or substantively similar marketing materials or received a test conducted or handled in a similar way. And like other members of the Class, Plaintiff purchased and paid for a Theranos blood test which he otherwise would not have paid for had the test been properly marketed based on truthful and accurate information or did not receive the test promised or due as a matter of law.



1           117. As a purchaser of Theranos' services, Plaintiff will fairly and adequately represent  
2 and protect the interests of the Class. Plaintiff and the Class are represented by counsel competent  
3 and experienced in both consumer protection and class action litigation.

4           118. Class certification is appropriate because common questions of law and fact  
5 substantially predominate over questions that may affect only individual members of the Class,  
6 including:

- 7                   a. Whether Theranos' blood tests were suitable or merchantable.  
8                   b. Whether Theranos' methodologies and equipment complied with industry,  
9 state, and federal standards.  
10                  c. Whether Theranos' blood tests were as represented or promised.  
11                  d. Whether Theranos' blood tests were of the highest accuracy and quality.  
12                  e. Whether Theranos misrepresented its tests were minimally invasive, accurate,  
13 and reliable.  
14                  f. Whether Theranos' conducted violation the UCL.  
15                  g. Whether Theranos' conducted violated California's false advertising laws.  
16                  h. Whether Theranos' conduct violated the Arizona Consumer Fraud Act.  
17                  i. Whether the challenged practices harmed Plaintiff and members of the Class;  
18 and  
19                  j. Whether Plaintiff and members of the Class are entitled to damages,  
20 restitution, equitable relief, and/or injunctive relief.

21           119. A class action is superior to other available methods for the fair and efficient  
22 adjudication of this controversy, since joinder of all the individual Class members is impracticable.  
23 Because the restitution and/or damages suffered, and continue to be suffered, by each individual  
24 Class member may be relatively small, the expense and burden of individual litigation would make it  
25 very difficult, if not impossible, for individual Class members to redress the wrongs done to each  
26 individually and the burden imposed on the judicial system would be enormous.

27           120. A class action is manageable, conserves judicial resources and the parties' resources,  
28 and protects the rights of each putative class member.

**VII. CAUSES OF ACTION**

**FIRST CAUSE OF ACTION  
(BREACH OF CONTRACT)**

121. Plaintiff incorporates the allegations in the above paragraphs as if fully set forth herein.

122. Defendant Theranos entered uniform or substantially similar contracts with class members to provide blood tests.

123. Theranos assured its customers it had the expertise and capability to provide accurate and reliable blood tests. Theranos promised that its tests were the most accurate and highest quality tests in the market.

124. For monetary consideration, Theranos agreed to provide blood testing using its proprietary system.

125. Plaintiff and putative Class members each paid money for the blood tests offered by Theranos. Plaintiff paid \$77.70 for the Reproductive Health blood tests and his insurer paid for routine blood work related to his annual physical.

126. Theranos breached its contract with Plaintiff and putative class members by (1) providing tests that were not of the promised high level of accuracy and quality, (2) conducting tests using traditional blood testing methodologies and equipment instead of its self-proclaimed minimally invasive state-of-the art proprietary system, (3) not drawing blood in the minimally invasive way advertised, (4) not ensuring its equipment met its own quality standards, (5) not ensuring its services were tendered with reasonable care and workmanlike effort, including failing to ensure its equipment met industry, state, or federal standards and failing to ensure lab staff was properly trained and monitored, and (7) failing to act in good faith and deal fairly with class members by acting to deprive class members of the justified expectations they were to receive under the contract, including failing to notify class members in a timely fashion of the deficiencies and problems with the tests or their results and not clarifying that certain services were conventional and no different than other blood tests on the market.



- 1 • Advertising it performs the highest quality testing in the industry when its testing  
2 procedures and equipment are flawed and fail to meet its own standards, standards  
3 set by the manufacturer, and industry, state, or federal standards.
- 4 • Advertises its goal is to give consumers actionable information but conceals and  
5 obfuscates on the methodologies of its tests.
- 6 • Failing to notify consumers in a timely manner that its tests were inaccurate and  
7 voidable despite knowing that the tests were not reliable or accurate.

8 133. Theranos intended that others rely on the concealment, suppression or omission of  
9 material facts by, among other things, promising to disclose the results of independent testing of its  
10 equipment and methodology but failing to do so.

11 134. Theranos has engaged in a pattern or practice of misrepresentation and deceptive  
12 conduct in the sale of blood testing services to consumers.

13 135. Theranos' actions were willful because it knew or should have known that the  
14 practices described in this Complaint violated the Consumer Fraud Act.

### 15 **THIRD CAUSE OF ACTION**

#### 16 **(VIOLATION OF THE UNFAIR COMPETITION ACT, 17 CALIFORNIA BUSINESS & PROFESSIONS CODE § 17200, ET SEQ.)**

18 136. Plaintiff incorporates by reference the allegations in the above paragraphs as if fully  
19 set forth herein.

20 137. Cal. Bus. & Prof. Code § 17200 prohibits any “unlawful, unfair, or fraudulent  
21 business act or practice.”

22 138. Theranos' conduct, as alleged in the Complaint, constituted and constitutes unfair,  
23 unlawful and fraudulent business practices in violation of Section 17200, et seq. of the California  
24 Business and Professions Code.

25 139. The conduct is unfair, unlawful, and fraudulent because Theranos breached its  
26 contract with Plaintiff and putative class members and engaged in false advertising under Section  
27 17500, et seq. of the California Business and Professions Code.

28 140. Defendant's conduct is unfair because it impairs competition within the market for  
blood tests. Theranos falsely advertises and claims its blood tests are minimally invasive, accurate,  
and reliable. Theranos' conduct prevents consumers from making fully informed decisions

1 regarding where to have their blood tests performed and by whom. Reasonable consumers are likely  
2 to be deceived by Defendant's false statements.

3 141. Defendant's conduct also offends established public policy supporting truth in  
4 advertising to consumers.

5 142. Defendant's conduct is unlawful because Theranos breached its contract with Plaintiff  
6 and putative class members and engaged in false advertising under Section 17500, *et seq.* of the  
7 California Business and Professions Code.

8 143. Defendant has violated the fraudulent prong of section 17200 because it  
9 misrepresentation and material omissions are likely to deceive a reasonable consumer and the facts  
10 would be material to a reasonable consumer.

11 144. Theranos' advertisements and public statements create the false impressions its blood  
12 tests are minimally invasive, reliable, and accurate when they are not.

13 145. Consumers can choose their blood test provider. Given that Theranos' blood tests are  
14 equally invasive to traditional tests, unreliable, and inaccurate, the economic harm to consumers who  
15 had their tests performed by Theranos over its competitors is obvious.

16 146. Theranos' misrepresentations and omissions were material, and likely to deceive  
17 reasonable consumers.

18 147. Theranos knew or should have known that the marketing and sale of its blood tests as  
19 minimally invasive, reliable, and accurate was deceptive.

20 148. Theranos had a duty to disclose the inherent flaws and limitations in its tests, and any  
21 inaccuracy and reliability problems before the tests were performed. Theranos also had a duty to  
22 disclose in a timely manner the fact that the tests were inaccurate and voidable. Theranos failed to  
23 fulfill these obligations.

24 149. Plaintiff and putative class members have suffered injury, including the loss of  
25 money, as result of Defendant's unlawful, unfair, and/or deceptive practices. Plaintiff and putative  
26 class members are accordingly entitled to disgorgement of Theranos' profits, plus interest and  
27 attorneys' fees, under California Code of Civil Procedure § 1021.5.

**FOURTH CAUSE OF ACTION**

**(CONSUMER LEGAL REMEDIES ACT.)  
(CAL. CIV. CODE § 1750, ET SEQ.)**

150. Plaintiff incorporates by reference the allegations in the above paragraphs as if fully set forth herein.

151. Defendant is a “person” under Cal. Civ. Code § 1761(c).

152. Plaintiff and putative class members are “consumers,” as defined by Cal. Civ. Code § 1761(d), who purchased blood tests from Theranos.

153. The blood tests are “goods or services” under Cal. Civ. Code § 1770(a).

154. Cal. Civ. Code § 1770(a)(5) prohibits “[r]epresenting that goods or services have sponsorship, approval, characteristics, ingredients, uses, benefits, or quantities which they do not have....”

155. Cal. Civ. Code § 1770(a)(7) prohibits “[r]epresenting that goods or services are of a particular standard, quality, or grade, or that goods are of a particular style or model, if they are of another.”

156. Theranos violated these CLRA provisions by its misrepresentations and omissions regarding the sponsorship, approval, certification, characteristics, benefits, standards, and quality of its blood testing in its advertising.

157. As alleged in the Complaint, Theranos creates the impression that it is providing consumers with the most advanced, accurate, least invasive, and highest quality testing available in the market. Theranos omits and fails to disclose that (1) its labs were negligently maintained and operated, and did not follow proper procedures and policies; (2) consumers did not receive revolutionary, fast, minimally invasive techniques on cutting edge technology promised by Theranos; (3) Theranos did not strive to provide accurate information to its consumers so they could make an informed choice despite promises to do so; (4) its promises that its tests are of the highest levels of accuracy and quality are unfounded, false and misleading; and (5) consumers are not getting what they paid for when they receive blood tests from Theranos.

1 158. Theranos' omissions are material. Reasonable consumers would consider the promise  
2 of minimally invasive, accurate, and reliable blood tests—indeed, the most accurate and highest  
3 quality tests according to Defendant—to be important in determining whether or not to purchase  
4 blood tests from Theranos or another provider.

5 159. Reasonable consumers were likely to be deceived, and were in fact misled, by  
6 Defendant's misrepresentations and omissions.

7 160. Theranos knew or reasonably should have known that the marketing and sale of its  
8 blood tests was and is deceptive.

9 161. Plaintiff and putative class members were directly and proximately injured by  
10 Theranos' conduct and lost money as a result of, and in reliance on, Defendant's misrepresentations  
11 and omissions, because they would not have purchased or paid as much for the Theranos blood tests  
12 had they been told the truth.

13 162. All of the wrongful conduct alleged herein occurred, and continues to occur, in the  
14 conduct of Defendant's business. Defendant's wrongful conduct is part of a general practice that is  
15 still being perpetuated and repeated.

16 163. In accordance with Civil Code § 1780 (a), Plaintiff and putative class members seek  
17 injunctive and equitable relief for Defendant's violations of the CLRA, including an injunction to  
18 enjoin Theranos from continuing its deceptive advertising and sales practices.

19 164. In accordance with Civil Code § 1782 (a) of the CLRA, Civ. Code § 1782(a), on  
20 May 26, 2016, Plaintiff's counsel served Defendant with notice of their alleged violations of the  
21 CLRA by certified mail, return receipt requested. After 30 days of the date of such notification,  
22 Defendant intends to amend his Complaint to maintain an action for damages under Section 1780 of  
23 the CLRA, Civ. Code § 1780.

24 **FIFTH CAUSE OF ACTION**

25 **(VIOLATION OF THE UNFAIR COMPETITION ACT,**  
26 **CALIFORNIA BUSINESS & PROFESSIONS CODE § 17500, ET SEQ.)**

27 165. Plaintiff incorporates by reference the allegations in the above paragraphs as if fully  
28 set forth herein.

1           166. California Business & Professions Code §§ 17500, et seq. (the “FAL”) broadly  
2           proscribes deceptive advertising in this State. Section 17500 makes it unlawful for any corporation  
3           intending to sell products or perform services to make any statement in advertising those products or  
4           services concerning any circumstance or matter of fact connected with the proposed performance or  
5           disposition thereof, which is untrue or misleading, and which is known, or which by exercising  
6           reasonable care would be known, to be untrue or misleading, or not to sell those products or services  
7           as advertised at the price stated therein, or as so advertised.

8           167. Theranos’ advertising creates the impression that its blood tests are minimally  
9           invasive, reliable, and highly accurate. Theranos claims its tests are the highest quality, most  
10          advanced tests available. All these statements are false.

11          168. Theranos fails to disclose its tests are equally invasive as its competitors’ tests,  
12          unreliable, and inaccurate. Theranos itself voided all tests performed by its proprietary Edison  
13          system between 2014 and 2015, as inaccurate and unreliable.

14          169. Theranos had a duty to disclose its tests were equally invasive as its competitors’  
15          tests, unreliable, and inaccurate before they were offered to consumers. Theranos failed to fulfill this  
16          duty.

17          170. Theranos had a duty to disclose its labs did not meet all industry, state, and federal  
18          standards before the tests were offered to consumers. Theranos failed to fulfill this duty.

19          171. Theranos’ omissions are material. Consumers are given the choice to have their blood  
20          tested at any facility. Reasonable consumers would consider the omitted facts to be important in  
21          determining whether to have their blood tested at a Theranos facility or elsewhere.

22          172. Reasonable consumers were likely to be deceived, and were misled, by Defendant’s  
23          misrepresentations and omissions.

24          173. Theranos knew or should have known that the marketing and sale of its blood tests  
25          was deceptive.

26          174. Plaintiff and putative class members have suffered injury, including the loss of  
27          money, because of Defendant’s conduct. Plaintiff and putative class members were directly and  
28          proximately injured by Defendant’s conduct and lost money because of, and in reliance on,



1 Defendant's misrepresentations and omissions, because they would not have purchased or paid as  
2 much for a Theranos blood test had they known that the tests were equally invasive, unreliable, and  
3 inaccurate.

4 175. All of the wrongful conduct alleged in the Complaint occurred, and continues to  
5 occur, in the conduct of Defendant's business. Defendant's wrongful conduct is part of a general  
6 practice that is still being perpetuated and repeated throughout the State of California and  
7 nationwide.

8 176. Plaintiff requests this Court enter such orders or judgments as may be necessary to  
9 enjoin Defendant from continuing its unfair and deceptive business practices, to restore to Plaintiff  
10 and putative class members any money that Defendant acquired by unfair competition, and to  
11 provide such other relief as set forth below.

12 **SIXTH CAUSE OF ACTION**

13 **(UNJUST ENRICHEMENT)**

14 177. Plaintiff incorporates the allegations in the above paragraphs as if fully set forth  
15 herein.

16 178. In the event that there is no legal contract between Theranos and putative class  
17 members, Plaintiff alleges the following, in the alternative to the breach of contract claim alleged in  
18 Count I, on behalf of himself and the putative class.

19 179. As the intended and expected result of its conscious wrongdoing as set forth in this  
20 Complaint, Theranos has profited and benefited from the unlawful sale of its misleading, unreliable,  
21 and inaccurate blood tests.

22 180. To the detriment of Plaintiff and putative class members, Theranos has been and  
23 continues to be unjustly enriched as a result of the unlawful and/or wrongful conduct alleged herein.

24 181. Theranos has voluntarily accepted and retained the fees paid by Plaintiff and putative  
25 class members with full knowledge and awareness that as a result of its unlawful conduct, Plaintiff  
26 and the putative class paid substantial monies to Theranos to which it was not lawfully entitled.

27 182. Plaintiff and putative class members paid for minimally invasive, accurate, and  
28 reliable blood tests, but received invasive, inaccurate and unreliable tests.

1 183. Between Theranos and Plaintiff/putative class members, it would be unjust for  
2 Theranos to retain the benefits attained by its wrongful actions.

3 184. Theranos has been unjustly enriched at the expense of Plaintiff and putative class  
4 members who are entitled in equity to disgorgement and restitution of Defendant's wrongful profits,  
5 revenue, and benefits, to the extent, and in the amount deemed appropriate by the court, and any  
6 other relief the court deems just and proper to remedy Defendant's unjust enrichment.

7 **REQUEST FOR RELIEF**

8 WHEREFORE, Plaintiff, individually and for members of the Class, respectfully request that  
9 the Court enter judgment in their favor and against Defendant, as follows:

10 A. Certification of the proposed Class, including appointment of Plaintiff's counsel as  
11 Class Counsel and Plaintiff as class representative;

12 B. An order temporarily and permanently enjoining Defendant from continuing the  
13 unlawful, deceptive, fraudulent, and unfair business practices alleged in this Complaint;

14 C. Costs, restitution, damages, including punitive damages, and disgorgement in an  
15 amount to be determined at trial;

16 D. An order requiring Defendant to pay both pre- and post-judgment interest on any  
17 amounts awarded;

18 F. An award of costs and attorneys' fees; and

19 G. Such other or further relief as may be appropriate.

20 **DEMAND FOR JURY TRIAL**

21 Plaintiff demands a jury trial for all claims so triable.  
22  
23  
24  
25  
26  
27  
28

1 DATED: May 26, 2016

HAGENS BERMAN SOBOL SHAPIRO LLP

2 By /s/ Shana E. Scarlett

3 Shana E. Scarlett (SBN 217895)

4 715 Hearst Avenue

Berkeley, California 94710

5 Telephone: (510) 725-3000

6 Facsimile: (510) 725-3001

[shanas@hbsslaw.com](mailto:shanas@hbsslaw.com)

7 Robert B. Carey (*Pro Hac Vice pending*)

8 Leonard Aragon (*Pro Hac Vice pending*)

9 Michella Kras (*Pro Hac Vice pending*)

10 11 West Jefferson, Suite 1000

Phoenix, Arizona 85003

11 Telephone: (602) 840-5900

12 Facsimile: (602) 840-3012

[rob@hbsslaw.com](mailto:rob@hbsslaw.com)

13 Steve W. Berman (*Pro Hac Vice pending*)

14 1918 8th Avenue, Suite 3300

Seattle, Washington 98101

15 Telephone: (206) 623-7292

16 Facsimile: (206) 623-0594

[steve@hbsslaw.com](mailto:steve@hbsslaw.com)

17 Attorneys for Plaintiff

CIVIL COVER SHEET

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.)

I. (a) PLAINTIFFS
CASEY JONES
(b) County of Residence of First Listed Plaintiff Maricopa County, AZ
(c) Attorneys (Firm Name, Address, and Telephone Number)
Shana E. Scarlett, Hagens Berman Sobol Shapiro LLP,
715 Hearst Ave., Suite 202, Berkeley, CA 94710; (510) 725-3000

DEFENDANTS
THERANOS, INC.
County of Residence of First Listed Defendant Santa Clara County, CA
NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE TRACT OF LAND INVOLVED.
Attorneys (If Known)

II. BASIS OF JURISDICTION (Place an "X" in One Box Only)
1 U.S. Government Plaintiff
2 U.S. Government Defendant
3 Federal Question (U.S. Government Not a Party)
4 Diversity (Indicate Citizenship of Parties in Item III)

III. CITIZENSHIP OF PRINCIPAL PARTIES (Place an "X" in One Box for Plaintiff and One Box for Defendant)
Citizen of This State PTF 1 DEF 1
Citizen of Another State PTF 2 DEF 2
Citizen or Subject of a Foreign Country PTF 3 DEF 3

IV. NATURE OF SUIT (Place an "X" in One Box Only)
CONTRACT: 110 Insurance, 120 Marine, 130 Miller Act, 140 Negotiable Instrument, 150 Recovery of Overpayment & Enforcement of Judgment, 151 Medicare Act, 152 Recovery of Defaulted Student Loans (Excludes Veterans), 153 Recovery of Overpayment of Veteran's Benefits, 160 Stockholders' Suits, 190 Other Contract, 195 Contract Product Liability, 196 Franchise.
REAL PROPERTY: 210 Land Condemnation, 220 Foreclosure, 230 Rent Lease & Ejectment, 240 Torts to Land, 245 Tort Product Liability, 290 All Other Real Property.
TORTS: PERSONAL INJURY (310 Airplane, 315 Airplane Product Liability, 320 Assault, Libel & Slander, 330 Federal Employers' Liability, 340 Marine, 345 Marine Product Liability, 350 Motor Vehicle, 355 Motor Vehicle Product Liability, 360 Other Personal Injury, 362 Personal Injury - Medical Malpractice), PERSONAL INJURY (365 Personal Injury - Product Liability, 367 Health Care/Pharmaceutical Personal Injury Product Liability, 368 Asbestos Personal Injury Product Liability), PERSONAL PROPERTY (370 Other Fraud, 371 Truth in Lending, 380 Other Personal Property Damage, 385 Property Damage Product Liability).
FORFEITURE/PENALTY: 625 Drug Related Seizure of Property 21 USC 881, 690 Other.
LABOR: 710 Fair Labor Standards Act, 720 Labor/Management Relations, 740 Railway Labor Act, 751 Family and Medical Leave Act, 790 Other Labor Litigation, 791 Employee Retirement Income Security Act.
IMMIGRATION: 462 Naturalization Application, 465 Other Immigration Actions.
BANKRUPTCY: 422 Appeal 28 USC 158, 423 Withdrawal 28 USC 157.
PROPERTY RIGHTS: 820 Copyrights, 830 Patent, 840 Trademark.
SOCIAL SECURITY: 861 HIA (1395ff), 862 Black Lung (923), 863 DIWC/DIWW (405(g)), 864 SSID Title XVI, 865 RSI (405(g)).
FEDERAL TAX SUITS: 870 Taxes (U.S. Plaintiff or Defendant), 871 IRS—Third Party 26 USC 7609.
OTHER STATUTES: 375 False Claims Act, 400 State Reapportionment, 410 Antitrust, 430 Banks and Banking, 450 Commerce, 460 Deportation, 470 Racketeer Influenced and Corrupt Organizations, 480 Consumer Credit, 490 Cable/Sat TV, 850 Securities/Commodities/Exchange, 890 Other Statutory Actions, 891 Agricultural Acts, 893 Environmental Matters, 895 Freedom of Information Act, 896 Arbitration, 899 Administrative Procedure Act/Review or Appeal of Agency Decision, 950 Constitutionality of State Statutes.

V. ORIGIN (Place an "X" in One Box Only)
1 Original Proceeding
2 Removed from State Court
3 Remanded from Appellate Court
4 Reinstated or Reopened
5 Transferred from Another District (specify)
6 Multidistrict Litigation

VI. CAUSE OF ACTION
Cite the U.S. Civil Statute under which you are filing (Do not cite jurisdictional statutes unless diversity):
28 U.S.C. sec. 1332 (d)(2)
Brief description of cause:
Consumer Fraud Class Action - Diversity

VII. REQUESTED IN COMPLAINT:
CHECK IF THIS IS A CLASS ACTION UNDER RULE 23, F.R.Cv.P. DEMAND \$
CHECK YES only if demanded in complaint: JURY DEMAND: Yes No

VIII. RELATED CASE(S) IF ANY
(See instructions): JUDGE Jacqueline Scott Corley DOCKET NUMBER 3:16-cv-02810-JSC

DATE 05/26/2016 SIGNATURE OF ATTORNEY OF RECORD /s/ Shana E. Scarlett

IX. DIVISIONAL ASSIGNMENT (Civil L.R. 3-2)
(Place an "X" in One Box Only)
SAN FRANCISCO/OAKLAND SAN JOSE EUREKA

## INSTRUCTIONS FOR ATTORNEYS COMPLETING CIVIL COVER SHEET FORM JS 44

### Authority For Civil Cover Sheet

The JS 44 civil cover sheet and the information contained herein neither replaces nor supplements the filings and service of pleading or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. Consequently, a civil cover sheet is submitted to the Clerk of Court for each civil complaint filed. The attorney filing a case should complete the form as follows:

- I.(a) Plaintiffs-Defendants.** Enter names (last, first, middle initial) of plaintiff and defendant. If the plaintiff or defendant is a government agency, use only the full name or standard abbreviations. If the plaintiff or defendant is an official within a government agency, identify first the agency and then the official, giving both name and title.
- (b) County of Residence.** For each civil case filed, except U.S. plaintiff cases, enter the name of the county where the first listed plaintiff resides at the time of filing. In U.S. plaintiff cases, enter the name of the county in which the first listed defendant resides at the time of filing. (NOTE: In land condemnation cases, the county of residence of the "defendant" is the location of the tract of land involved.)
- (c) Attorneys.** Enter the firm name, address, telephone number, and attorney of record. If there are several attorneys, list them on an attachment, noting in this section "(see attachment)".
- II. Jurisdiction.** The basis of jurisdiction is set forth under Rule 8(a), F.R.Cv.P., which requires that jurisdictions be shown in pleadings. Place an "X" in one of the boxes. If there is more than one basis of jurisdiction, precedence is given in the order shown below.  
 United States plaintiff. (1) Jurisdiction based on 28 U.S.C. 1345 and 1348. Suits by agencies and officers of the United States are included here.  
 United States defendant. (2) When the plaintiff is suing the United States, its officers or agencies, place an "X" in this box.  
 Federal question. (3) This refers to suits under 28 U.S.C. 1331, where jurisdiction arises under the Constitution of the United States, an amendment to the Constitution, an act of Congress or a treaty of the United States. In cases where the U.S. is a party, the U.S. plaintiff or defendant code takes precedence, and box 1 or 2 should be marked.  
 Diversity of citizenship. (4) This refers to suits under 28 U.S.C. 1332, where parties are citizens of different states. When Box 4 is checked, the citizenship of the different parties must be checked. (See Section III below; **NOTE: federal question actions take precedence over diversity cases.**)
- III. Residence (citizenship) of Principal Parties.** This section of the JS 44 is to be completed if diversity of citizenship was indicated above. Mark this section for each principal party.
- IV. Nature of Suit.** Place an "X" in the appropriate box. If the nature of suit cannot be determined, be sure the cause of action, in Section VI below, is sufficient to enable the deputy clerk or the statistical clerk(s) in the Administrative Office to determine the nature of suit. If the cause fits more than one nature of suit, select the most definitive.
- V. Origin.** Place an "X" in one of the six boxes.  
 Original Proceedings. (1) Cases which originate in the United States district courts.  
 Removed from State Court. (2) Proceedings initiated in state courts may be removed to the district courts under Title 28 U.S.C., Section 1441. When the petition for removal is granted, check this box.  
 Remanded from Appellate Court. (3) Check this box for cases remanded to the district court for further action. Use the date of remand as the filing date.  
 Reinstated or Reopened. (4) Check this box for cases reinstated or reopened in the district court. Use the reopening date as the filing date.  
 Transferred from Another District. (5) For cases transferred under Title 28 U.S.C. Section 1404(a). Do not use this for within district transfers or multidistrict litigation transfers.  
 Multidistrict Litigation. (6) Check this box when a multidistrict case is transferred into the district under authority of Title 28 U.S.C. Section 1407. When this box is checked, do not check (5) above.
- VI. Cause of Action.** Report the civil statute directly related to the cause of action and give a brief description of the cause. **Do not cite jurisdictional statutes unless diversity.** Example: U.S. Civil Statute: 47 USC 553 Brief Description: Unauthorized reception of cable service
- VII. Requested in Complaint.** Class Action. Place an "X" in this box if you are filing a class action under Rule 23, F.R.Cv.P.  
 Demand. In this space enter the actual dollar amount being demanded or indicate other demand, such as a preliminary injunction.  
 Jury Demand. Check the appropriate box to indicate whether or not a jury is being demanded.
- VIII. Related Cases.** This section of the JS 44 is used to reference related pending cases, if any. If there are related pending cases, insert the docket numbers and the corresponding judge names for such cases.

**Date and Attorney Signature.** Date and sign the civil cover sheet.